Latest & greatest articles for constipation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on constipation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on constipation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for constipation

61. Prucalopride (Resolor) for adult males with chronic constipation ? third line

Prucalopride (Resolor) for adult males with chronic constipation ? third line Prucalopride (Resolor) for adult males with chronic constipation – third line Prucalopride (Resolor) for adult males with chronic constipation – third line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prucalopride (Resolor) for adult males (...) with chronic constipation – third line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Benzofurans; Chronic Disease; Constipation; Laxatives; Male Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public

Health Technology Assessment (HTA) Database.2014

62. Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain

Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Methylnaltrexone bromide (Relistor) for opioid-induced constipation in adult patients with chronic non-malignant pain. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioid; Constipations; Naltrexone; Narcotic Antagonists Language Published English Country of organisation England English summary

Health Technology Assessment (HTA) Database.2014

63. Interventions for treating postpartum constipation.

Interventions for treating postpartum constipation. BACKGROUND: Constipation is a functional bowel disorder that can reduce quality of life in the puerperium period. The diagnosis of postpartum constipation is both subjective and objective. It is characterised by symptoms such as pain or discomfort, straining, hard lumpy stools and a sense of incomplete bowel evacuation. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones and hematinics used in pregnancy can increase (...) the risk of postpartum constipation. Although a high fibre diet and increased fluid intake is encouraged to assist defecation in the puerperium, pain-relieving drugs and laxatives are common drugs of choice to alleviate constipation. However, the effectiveness and safety of laxatives on the nursing mother need to be ascertained. OBJECTIVES: To evaluate the effectiveness of interventions for treating postpartum constipation. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's

Cochrane2014

64. Lubiprostone, 24 micrograms soft capsules (Amitiza) - the treatment of chronic idiopathic constipation

Lubiprostone, 24 micrograms soft capsules (Amitiza) - the treatment of chronic idiopathic constipation

Scottish Medicines Consortium2014

66. Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation

Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation TITLE: Dioctyl Sulfosuccinate or Docusate (Calcium or Sodium) for the Prevention or Management of Constipation: A Review of the Clinical Effectiveness DATE: 26 June 2014 CONTEXT AND POLICY ISSUES Constipation has many definitions and is often described differently depending on the population queried. Many physicians define constipation as a reduction in the frequency of bowel movements (...) to fewer than three times per week while patients identify more with the symptoms associated with constipation such as difficulty passing stool, hard stool consistency, feelings of abdominal cramping, and feelings of incomplete stool passage. 1 Causes of constipation may be primary (idiopathic) or secondary to other factors such as diet, medication, or medical conditions. 2 Constipation can affect anyone as a minor annoyance but up to a quarter of the population experiences it chronically or severely

Canadian Agency for Drugs and Technologies in Health - Rapid Review2014

67. Docusate for treatment of constipation

Docusate for treatment of constipation Docusate for treatment of constipation Docusate for treatment of constipation Mitchell MD, Williams K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Williams K. Docusate for treatment of constipation. Philadelphia: Center for Evidence-based Practice (CEP). 2014 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Constipation; Dioctyl Sulfosuccinic Acids Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber 32014000628 Date abstract record published 17/06/2014 Health Technology Assessment (HTA) database Copyright © 2017

Health Technology Assessment (HTA) Database.2014

68. Biofeedback for treatment of chronic idiopathic constipation in adults.

Biofeedback for treatment of chronic idiopathic constipation in adults. BACKGROUND: Biofeedback therapy has been used to treat the symptoms of people with chronic constipation referred to specialist services within secondary and tertiary care settings. However, different methods of biofeedback are used within different centres and the magnitude of suggested benefits and comparable effectiveness of different methods of biofeedback has yet to be established. OBJECTIVES: To determine the efficacy (...) and safety of biofeedback for the treatment of chronic idiopathic (functional) constipation in adults. SEARCH METHODS: We searched the following databases from inception to 16 December 2013: CENTRAL, the Cochrane Complementary Medicine Field, the Cochrane IBD/FBD Review Group Specialized Register, MEDLINE, EMBASE, CINAHL, British Nursing Index, and PsychINFO. Hand searching of conference proceedings and the reference lists of relevant articles was also undertaken. SELECTION CRITERIA: All randomised

Cochrane2014

69. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis

Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis Ford AC, Brenner DM, Schoenfeld PS CRD summary This review found that μ-opioid receptor antagonists were safe and effective (...) for the treatment of opioid-induced constipation. There was some concern over uncertain trial quality but the results appear to be reliable. The conclusion on safety may be overstated given the evidence. Authors' objectives To investigate the evidence for the benefits of pharmacological therapies for opiate-induced constipation. Searching MEDLINE, EMBASE and Cochrane CENTRAL were searched to December 2012 without language restrictions. Search terms were presented. Conference proceedings and reference lists

DARE.2014

70. Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain.

Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. 24896818 2014 06 19 2014 07 08 2016 10 25 1533-4406 370 25 2014 Jun 19 The New England journal of medicine N. Engl. J. Med. Naloxegol for opioid-induced constipation in patients with noncancer pain. 2387-96 10.1056/NEJMoa1310246 Opioid-induced constipation is common and debilitating. We investigated the efficacy and safety of naloxegol, an oral, peripherally acting, μ-opioid receptor antagonist, for the treatment (...) of opioid-induced constipation. In two identical phase 3, double-blind studies (study 04, 652 participants; study 05, 700 participants), outpatients with noncancer pain and opioid-induced constipation were randomly assigned to receive a daily dose of 12.5 or 25 mg of naloxegol or placebo. The primary end point was the 12-week response rate (≥3 spontaneous bowel movements per week and an increase from baseline of ≥1 spontaneous bowel movements for ≥9 of 12 weeks and for ≥3 of the final 4 weeks

NEJM2014

71. Movantik (naloxegol) - To treat opioid-induced constipation in adults with chronic non-cancer pain

Movantik (naloxegol) - To treat opioid-induced constipation in adults with chronic non-cancer pain Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - MOVANTIK (naloxegol) Tablets Company: AstraZeneca Pharmaceuticals LP Application No.: 204760 Approval Date: 9/16/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

FDA - Drug Approval Package2014

72. Treatments for constipation: a review of systematic reviews

Treatments for constipation: a review of systematic reviews Treatments for constipation: a review of systematic reviews Treatments for constipation: a review of systematic reviews CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Treatments for constipation: a review of systematic reviews. Ottawa: Canadian Agency for Drugs (...) and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions In adults and children with chronic constipation, polyethylene glycol (PEG), increased the frequency of stools relative to placebo, lactulose and milk of magnesia. Stool frequency was also increased in adults treated with prucalopride versus placebo. Laxatives and prucalopride may increase the risk of diarrhea. No conclusions can be drawn with regards to stool softeners or bulking agents. The available studies were generally of lower

Health Technology Assessment (HTA) Database.2014

73. Constipation

Constipation TREATMENT OF CONSTIPATION IN PREGNANCY 0344 892 0909 TREATMENT OF CONSTIPATION IN PREGNANCY (Date of issue: November 2013 , Version: 1.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Constipation is a common complaint in pregnancy (...) and affects approximately 40% of women. It is thought to be caused by progesterone-induced intestinal smooth muscle relaxation. There is very little published epidemiological information available on the potential risks associated with the use of laxatives during pregnancy, however most have minimal systemic absorption and are commonly used during pregnancy without concerns regarding teratogenic effects being raised. Initial treatment of constipation in pregnancy should be non-pharmacological e.g

UK Teratology Information Service2014

74. The role of endoscopy in the management of constipation

The role of endoscopy in the management of constipation GUIDELINE The role of endoscopy in the management of constipation This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Stan- dards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this guideline. Inpreparingthisdocument,MEDLINEdatabaseswereused to search for publications pertaining to this topic between January 1990 and December 2013 (...) of thepatient’scondition and available coursesof action. Therefore,clinical considerations mayleadan endoscop- ist to take a course of action that varies from the recom- mendations and suggestions proposed in this document. INTRODUCTION AND EPIDEMIOLOGY Constipation is a common symptom affecting 2% to 27% of the population and resulting in about 2.5 million physician visits in the United States annually. 2,3 The preva- lence of constipation is higher in women than in men 4 and increases with age. 5 Low socioeconomic

American Society for Gastrointestinal Endoscopy2014

75. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN

Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations from ESPGHAN and NASPGHAN Copyright 2014 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited. Evaluation and Treatment of Functional Constipation in Infants and Children: Evidence-Based Recommendations From ESPGHAN and NASPGHAN M.M. Tabbers, C. DiLorenzo, M.Y. Berger, C. Faure, M.W. Langendam, S. Nurko, A. Staiano, Y. Vandenplas, and M.A. Benninga ABSTRACT (...) Background:Constipationisapediatricproblemcommonlyencounteredby many health care workers in primary, secondary, and tertiary care. To assist medical care providers in the evaluation and management of children with functional constipation, the North American Society for Pediatric Gastro- enterology,Hepatology,andNutritionandtheEuropeanSocietyforPediatric Gastroenterology, Hepatology, and Nutrition were charged with the task of developing a uniform document of evidence-based guidelines. Methods: Nine clinical questions addressing diagnostic, therapeutic

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition2014

76. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness

Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness CADTH Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions There remains a paucity of good quality evidence to support the use of docusate

Health Technology Assessment (HTA) Database.2014

77. Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review

Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review Stein E, Berger Z, Hutfless S, Shah L, Wilson LM, Haberl E, Bass (...) EB, Clarke JO Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stein E, Berger Z, Hutfless S, Shah L, Wilson LM, Haberl E, Bass EB, Clarke JO. Wireless motility capsule versus other diagnostic technologies for evaluating gastroparesis and constipation: a comparative effectiveness review. Rockville: Agency for Healthcare Research and Quality

Health Technology Assessment (HTA) Database.2013

78. Methylnaltrexone bromide (Relistor) for opioid-induced constipation

Methylnaltrexone bromide (Relistor) for opioid-induced constipation Methylnaltrexone bromide (Relistor) for opioid-induced constipation Methylnaltrexone bromide (Relistor) for opioid-induced constipation NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Methylnaltrexone bromide (Relistor) for opioid-induced constipation (...) . Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics, Opioids; Constipation; Laxatives; Naltrexone Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University

Health Technology Assessment (HTA) Database.2013

79. Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: A Comparative Effectiveness Review

Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: A Comparative Effectiveness Review

Effective Health Care Program (AHRQ)2013

80. Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: Future Research Needs

Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: Future Research Needs

Effective Health Care Program (AHRQ)2013